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Abstract: Neovascular glaucoma (NVG) secondary to internal carotid artery (ICA) occlusion 
is usually resistant to treatment. We report a case of NVG with ICA occlusion improved by 
intravitreal bevacizumab (IVB) injection and carotid artery stent replacement (CAS), even 
though we did not perform panretinal photocoagulation. A 67-year-old male with NVG noted 
visual loss in his left eye. Magnetic resonance angiography showed left ICA occlusion. He was 
diagnosed with NVG secondary to ICA occlusion. The next day, we carried out IVB injection in 
his left eye, following which the iris and angle neovascularization regressed, and the intraocular 
pressure decreased to normal within a day after the injection. CAS was performed on his left 
ICA at a month post injection. Two months later, we reinjected bevacizumab in his left eye. 
His condition remained stable with no recurrence over two years. This case indicates that IVB 
injection and CAS are useful for early-stage NVG secondary to ICA occlusion.
Keywords: bevacizumab, neovascular glaucoma, internal carotid artery occlusion, carotid 
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Introduction
Patients with internal carotid artery (ICA) occlusion/stenosis develop ocular ischemia 
and present with various ocular signs. The clinical course and presentation may be quite 
varied, with some cases showing rapid advancement of neovascularization following 
high intraocular pressure (IOP). ICA occlusion often progresses without symptoms, 
and when the patient notices ocular disorders and visits a clinic, the condition is often 
at an advanced stage of ocular ischemia where neovascular glaucoma (NVG) has 
developed with severe ICA stenosis. In such cases, due to the remarkable decline in 
ophthalmic arterial blood pressure, even a slight increase in IOP causes severe   damage 
to the eye and leads to loss of vision. Prompt countermeasures to lower IOP are essen-
tial to ameliorate the ischemia.1 Thorough panretinal photocoagulation (PRP) is the 
most effective procedure performed to resolve neovascularization, but sometimes the 
desired decline in IOP cannot be reached. In such cases, an invasive filtering surgical 
procedure, such as trabeculectomy, is needed to lower IOP.
Recently, the involvement of vascular endothelial growth factor (VEGF) in neo-
vascular diseases has been discussed.2 Bevacizumab is an anti-VEGF antibody and 
angiogenesis inhibitor developed in the US and approved in 2004 by the Food and Drug 
Administration as a treatment for colorectal cancer. It has also been used off-label for 
ocular diseases, and its efficacy has been reported for choroidal neovascularization in 
age-related macular degeneration and myopic choroidal neovascularization,   central 
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other ocular diseases.3–9 Because ocular administration of 
bevacizumab is not yet approved, its off-label use needs 
approval of the relevant institutional review board and   written 
consent of the patient, after a detailed explanation of the 
drug’s effects and confirmation of the patient’s free will in 
undertaking the treatment. This article describes the efficacy 
of intravitreal bevacizumab (IVB) injection in a patient with 
NVG secondary to ICA occlusion.
Case report
A 67-year-old male had intermittent vision difficulty and trou-
ble with seeing things in purple with his left eye since April 
2006, but did not pursue treatment until he gradually sensed 
decreasing visual acuity (VA). He visited a nearby clinic on 
April 26, 2007, when he was diagnosed with NVG. He was 
referred to Kinki University Hospital on April 27, 2007. At 
his initial visit to our hospital, his VA was 1.0 for both eyes, 
with IOP values of 13 mmHg OD and 31 mmHg OS. He 
had a 30-year history of type 2 diabetes mellitus. Slit lamp 
examination of his left eye demonstrated neovascularization 
of the iris and all hours of the angle, and peripheral anterior 
synechiae (PAS) was present at the directions of 3 o’clock and 
6 o’clock (Figure 1A and 1B). Funduscopy revealed periph-
eral blot hemorrhages in both eyes (Figure 1C). Fluorescein 
angiography (FA) revealed that the arm-to-retina circulation 
time was prolonged to 21.9 sec, and the intraretinal transit 
time was also prolonged. At the late phase of FA, diffuse leak-
age was seen, probably caused by hyperpermeability of the 
retinal artery, but no avascular areas were seen in his left eye 
(Figure 2A). We referred him to our neurosurgery department 
for examination. Magnetic resonance angiography (MRA) of 
his carotid arteries demonstrated branching of the left ICA 
from the common carotid artery and occlusion at 15.59 mm 
from the branching point (Figure 3).
The patient was diagnosed with ocular ischemic 
syndrome secondary to ICA occlusion. He had also had a 
cerebral infarction two years previously and was diagnosed 
at that time with ICA occlusion, but was given only oral 
antiplatelet medication and followed up.
In order to regress the neovascularization, 1.25 mg 
(0.05 mL) of bevacizumab (Avastin® 100 mg/4 mL) was 
injected into the vitreous through the pars plana of the left 
eye on April 28, 2007. Before the injection of bevacizumab, 
approval from the institutional review board of Kinki 
  University Hospital and the patient’s informed consent 
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Figure 2 Fluorescein angiography of the left eye shown over time. A) At the 
initial visit. B) six months after carotid artery stent replacement. Angiogram taken   
six months after carotid artery stent replacement shows normalized arm-to-retina 
circulation time and the leakage of the dye from the retinal artery was improved, 
with no avascular areas observed.
Figure 3 Magnetic resonance angiography of the carotid, showing occlusion of the 
left carotid artery at 15.59 mm from its branching from the common carotid artery.
A
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Figure 1 Clinical findings at the initial patient visit. A) Neovascularization of the 
the iris. B) Neovascularization of the angle. C) The fundus photograph of both eyes. 
The images show bilateral peripheral dot hemorrhages.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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were obtained. On the following day, the left eye IOP 
decreased to 18 mmHg and iris neovascularization vanished. 
Five days after the injection, the neovascularization at the 
angle had completely regressed, and left eye IOP remained 
18 mmHg. The patient did not show any signs of deteriora-
tion, so we decided to follow him up without giving PRP. He 
underwent carotid artery angioplasty and stent placement on 
June 5, 2007. After the operation, the VA was 1.0 for both eyes 
with IOP of 17 mmHg OD and 16 mmHg OS. However, neo-
vascularization was present at the directions of 3 o’clock and 
6 o’clock, so we injected bevacizumab (1.25 mg/0.05 mL) 
again into the left eye. After the reinjection, his corrected 
VA remained at more than 1.0. He did not report any com-
plications, and no evidence of IOP elevation or recurrence 
of neovascularization was seen. The funduscopic findings 
were improved, with only slight blot hemorrhage remaining 
(Figure 4). No complications associated with the IVB injec-
tion were identified. FA at six months after carotid artery stent 
placement (CAS) showed improvement of the arm-to-retina 
circulation time and the leakage of the dye from the blood 
vessels (Figure 2B). Avascular areas of the retina were not 
observed. More than two years have passed and his condition 
remains stable, although additional treatment, such as PRP, 
has not been performed (Figure 5A and 5B).
Discussion
We report here our experience with a case where NVG 
regressed and good VA was maintained following IVB 
injection without PRP. Bevacizumab treatment resolved 
iridal and angle rubeosis and lowered IOP quickly after 
the injection.
Conventionally, complete PRP has been the only estab-
lished method of treatment for neovascularization. However, 
PRP is a destructive method, and substantial lowering of visual 
function often occurs. To the best of our knowledge, there have 
been no reports that the combination of IVB and CAS resulted 
in a favorable long-term prognosis for NVG secondary to ICA 
occlusion without necessitating PRP application.
Because PRP has the advantage of permanent neovascular 
suppression, we have considered whether this procedure 
might be necessary in this case, and if necessary, when the 
most appropriate timing for PRP application might occur. 
However, two years have passed without any signs of neo-
vascular recurrence and our patient remains stable and in a 
good condition.
When we attend a patient with NVG, we have to treat 
the underlying causes, and nosotropic measures are also 
necessary to counter the symptoms of NVG. For a case like 
the present one, while giving carotid endarterectomy (CEA) 
or CAS as a fundamental treatment, we have to prescribe 
measures to resolve neovascularization and to suppress the 
development of secondary-angle glaucoma.
The fundamental therapy for this type of case is to 
improve ocular ischemia by widening the ischemic part 
of the ICA and reconstructing the blood circulation. The 
“gold standard” for treatment of an occluded ICA is CEA, a 
surgical treatment, and its effectiveness has been shown in 
many studies. For some cases in which CEA is considered 
a high-risk procedure, CAS has been performed, and it has 
been reported to be as effective as CEA.10 Our case was given 
CAS, and thereafter blood circulation was restored, and his 
funduscopic and FA findings have improved remarkably, and 
neovascularization in the iris and angle has been resolved.
On the other hand, there are reports of complications 
caused by CAS, therefore we need to judge the indication 
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Figure 4 Fundus photos of the left eye showing the clinical course. A) Five days after 
intravitreal bevacizumab injection. B) Thirty-two days after intravitreal bevacizumab 
injection. C) Forty-four days after carotid artery stent replacement. D) six months 
after carotid artery stent replacement. The photo taken 44 days after carotid artery 
stent replacement shows slight dot hemorrhages remaining; this hemorrhage was 
resolved by six months after carotid artery stent replacement.
A
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Figure 5 Fundus photos over time. A) One year after intravitreal bevacizumab 
injection. B) Two years after intravitreal bevacizumab injection. Ophthalmoscopy 
shows an almost normal fundus.Clinical Ophthalmology
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for CAS very carefully. While waiting for the operation to 
become feasible, we need to control IOP and give treatment 
to resolve neovascularization.
Recently, IVB injection has been reported to be very 
useful for NVG in the early stages.7 The clinical course of 
NVG is divided into three stages, ie, Stage I (preglaucoma), 
Stage II (open-angle glaucoma), and Stage III (angle-closure 
glaucoma).11
Wakabayashi et al7 reported their IOP control outcomes 
in patients with NVG who had received IVB injection as 
an initial treatment, although most of their cases had NVG 
secondary to diabetic retinopathy. Their findings show that 
IVB was very effective at the preglaucoma stage or early 
neovascularization stages, but IOP control was increasingly 
difficult with more advanced NVG.
Our patient was diagnosed with Stage II NVG (open-angle 
glaucoma), and the IVB injection produced prompt resolution 
of the neovascularization, resulting in a lowering of IOP, as 
well as suppression of angle-closure development.
As stated, IVB injection has the advantages of rapid 
and dramatic efficacy with low invasiveness. However, it 
is not flawless. The ocular use of bevacizumab is not yet 
approved by regulatory agencies, so we need institutional 
review board approval and adequate informed consent from 
the patient. Proper administration methods, correct dosages, 
and long-term patient prognosis have not yet been identi-
fied. The effect of an IVB injection is estimated at present 
to persist for one to several months and there is a chance 
of recurrence. Furthermore, there are some researchers12 
reporting a high probability of IOP increase immediately 
after intravitreal injection, therefore we need to assess the 
damage to the optic nerve caused by the injection using 
a larger number of cases. The left eye in our case had 
decreased IOP the day after the injection, and we presume 
this is showing the efficacy of bevacizumab injection in IOP 
reduction. Fortunately, we have not experienced deterioration 
of the visual field. On the other hand, the IOP of the right 
eye was 17 mmHg one month after the injection, but it has 
been fluctuating between 11 mmHg and 18 mmHg for two 
years afterwards. We consider this to be within the diurnal 
variation for the right eye.
Future study is needed to identify countermeasures for 
cases where the angle is already closed, where systemic 
complications are hindering neurosurgical procedures, where 
neurosurgical operations are not indicated (such as prolifera-
tive vascular occlusive disease), and where ocular circulation 
is not improved even after a neurosurgical procedure.
In conclusion, IVB injection can be a useful treatment for 
NVG secondary to ICA occlusion. While waiting for surgery 
like CEA or CAS as a fundamental treatment, we are able to 
control IOP quickly with IVB to suppress the development 
of secondary-angle glaucoma and maintain visual function 
for the patient.
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